공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 오피오이드 시장

Opioids

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품 코드 997522
페이지 정보 영문 271 Pages
가격
US $ 5,450 ₩ 6,193,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 16,350 ₩ 18,580,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 오피오이드 시장 Opioids
발행일 : 2021년 04월 페이지 정보 : 영문 271 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 오피오이드 시장 규모는 분석기간(2020-2027년)에 3.3%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 254억 달러에서 2027년에는 319억 달러에 달할 것으로 예측됩니다.

본 보고서에서 분석한 부문 중 하나인 즉시방출/단시간 작용 오피오이드(Immediate-Release/Short-Acting Opioid)는 분석기간 중 2.5%의 CAGR을 나타내고, 160억 달러에 달할 전망입니다.

세계의 오피오이드(Opioids) 시장에 대해 조사했으며, 시장 점유율, COVID-19의 영향, 동향 및 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 예

  • Egalet Corporation
  • Janssen Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Purdue Pharma LP
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • West-Ward Pharmaceuticals Corporation

목차

I. 조사 방법

II. 개요

  • 시장 개요
    • 인플루언서 시장 인사이트
    • 세계 시장 궤적
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기침체
  • 주요 기업
  • 동향 및 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

IV. 경쟁

  • 기업 개요 : 31개사
LSH 21.04.08

Abstract:

Global Opioids Market to Reach $31.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Opioids estimated at US$25.4 Billion in the year 2020, is projected to reach a revised size of US$31.9 Billion by 2027, growing at aCAGR of 3.3% over the period 2020-2027. Immediate-Release/Short-Acting Opioid, one of the segments analyzed in the report, is projected to record 2.5% CAGR and reach US$16 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Extended-Release/Long-Acting Opioid segment is readjusted to a revised 4.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $6.9 Billion, While China is Forecast to Grow at 5.9% CAGR

The Opioids market in the U.S. is estimated at US$6.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Select Competitors (Total 31 Featured) -

  • Egalet Corporation
  • Janssen Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Purdue Pharma LP
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • West-Ward Pharmaceuticals Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Immediate-Release/Short-Acting Opioid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Immediate-Release/Short-Acting Opioid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Immediate-Release/Short-Acting Opioid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Extended-Release/Long-Acting Opioid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Extended-Release/Long-Acting Opioid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Extended-Release/Long-Acting Opioid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Pain Relief by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Pain Relief by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Pain Relief by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Anesthesia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Anesthesia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Anesthesia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Cough Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Cough Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Cough Suppression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Diarrhea Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Diarrhea Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Diarrhea Suppression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Deaddiction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Deaddiction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Deaddiction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 37: Japan Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 40: Japan Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 43: China Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 46: China Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 49: Europe Current & Future Analysis for Opioids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Opioids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 58: France Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 61: France Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 64: Germany Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 67: Germany Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 70: Italy Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 73: Italy Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 76: UK Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 79: UK Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 82: Spain Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Spain Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Spain 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 85: Spain Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Spain Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Spain 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 88: Russia Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Russia Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Russia 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 91: Russia Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Russia Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Russia 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 94: Rest of Europe Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Europe Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Europe 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 97: Rest of Europe Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of Europe Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of Europe 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 100: Asia-Pacific Current & Future Analysis for Opioids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Opioids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 103: Asia-Pacific Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Asia-Pacific Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Asia-Pacific 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 106: Asia-Pacific Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Asia-Pacific Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Asia-Pacific 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 109: Australia Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Australia Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Australia 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 112: Australia Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Australia Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Australia 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 115: India Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: India Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: India 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 118: India Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: India Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: India 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 121: South Korea Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: South Korea Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: South Korea 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 124: South Korea Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: South Korea Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: South Korea 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 127: Rest of Asia-Pacific Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of Asia-Pacific Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 130: Rest of Asia-Pacific Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of Asia-Pacific Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of Asia-Pacific 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 133: Latin America Current & Future Analysis for Opioids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 134: Latin America Historic Review for Opioids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Latin America 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 136: Latin America Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Latin America Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Latin America 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 139: Latin America Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Latin America Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Latin America 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 142: Argentina Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Argentina Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Argentina 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 145: Argentina Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Argentina Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Argentina 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 148: Brazil Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Brazil Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Brazil 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 151: Brazil Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Brazil Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Brazil 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 154: Mexico Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Mexico Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Mexico 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 157: Mexico Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Mexico Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Mexico 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 160: Rest of Latin America Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Rest of Latin America Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Rest of Latin America 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 163: Rest of Latin America Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Rest of Latin America Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Rest of Latin America 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 166: Middle East Current & Future Analysis for Opioids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 167: Middle East Historic Review for Opioids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Middle East 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 169: Middle East Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Middle East Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Middle East 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 172: Middle East Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Middle East Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Middle East 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 175: Iran Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Iran Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Iran 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 178: Iran Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Iran Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Iran 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 181: Israel Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Israel Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Israel 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 184: Israel Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Israel Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Israel 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 187: Saudi Arabia Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Saudi Arabia Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Saudi Arabia 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 190: Saudi Arabia Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Saudi Arabia Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Saudi Arabia 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 193: UAE Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: UAE Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: UAE 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 196: UAE Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: UAE Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: UAE 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 199: Rest of Middle East Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Rest of Middle East Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Rest of Middle East 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 202: Rest of Middle East Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Rest of Middle East Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Rest of Middle East 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 205: Africa Current & Future Analysis for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Africa Historic Review for Opioids by Segment - Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Africa 15-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027
    • TABLE 208: Africa Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Africa Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Africa 15-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 31
Back to Top
전화 문의
F A Q